- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Leukemia Research and Treatment
Volume 2011 (2011), Article ID 428960, 4 pages
Wnt/ß-Catenin: A New Therapeutic Approach to Acute Myeloid Leukemia
Department of Internal Medicine III, Center for Integrated Oncology (CIO), University of Bonn, Sigmund-Freud-Straße 25, 53105 Bonn, Germany
Received 30 August 2011; Accepted 21 October 2011
Academic Editor: Spiro Konstantinov
Copyright © 2011 Y. Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. G. Gilliland, C. T. Jordan, and C. A. Felix, “The molecular basis of leukemia,” Hematology, pp. 80–97, 2004.
- T. Lapidot, C. Sirard, J. Vormoor et al., “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” Nature, vol. 367, no. 6464, pp. 645–648, 1994.
- S. W. Lane, Y. J. Wang, C. Lo Celso et al., “Differential niche and Wnt requirements during acute myeloid leukemia progression,” Blood, vol. 118, no. 10, pp. 2849–2856, 2011.
- Y. Okuhashi, M. Itoh, N. Nara, and S. Tohda, “Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells,” Anticancer Research, vol. 31, no. 3, pp. 893–896, 2011.
- A. Gandillet, S. Park, F. Lassailly et al., “Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation,” Leukemia, vol. 25, no. 5, pp. 770–780, 2011.
- L. H. Mochmann, J. Bock, J. Ortiz-Tánchez et al., “Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG,” Oncogene, vol. 30, no. 17, pp. 2044–2056, 2011.
- E. K. Siapati, M. Papadaki, Z. Kozaou et al., “Proliferation and bone marrow engraftment of AML blasts is dependent on β-catenin signalling,” The British Journal of Haematology, vol. 152, no. 2, pp. 164–174, 2011.
- E. A. Griffiths, S. D. Gore, C. Hooker et al., “Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation,” Leukemia and Lymphoma, vol. 51, no. 9, pp. 1711–1719, 2010.
- C. J. Eaves and R. K. Humphries, “Acute myeloid leukemia and the Wnt pathway,” The New England Journal of Medicine, vol. 362, no. 24, pp. 2250–2327, 2010.
- Y. Wang, A. V. Krivtsov, A. U. Sinha et al., “The Wnt/β-catenin pathway is required for the development of leukemia stem cells in AML,” Science, vol. 327, no. 5973, pp. 1650–1653, 2010.
- M. Schmidt, Y. Kim, S. -M. Gast et al., “Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid,” In Vivo, vol. 25, no. 3, pp. 325–333, 2011.
- Y. Kim, G. Reifenberger, D. Lu et al., “Influencing the Wnt signaling pathway in multiple myeloma,” Anticancer Research, vol. 31, no. 2, pp. 725–730, 2011.
- K. M. Cadigan and Y. I. Liu, “Wnt signaling: complexity at the surface,” Journal of Cell Science, vol. 119, no. 3, pp. 395–402, 2006.
- J. R. Miller, A. M. Hocking, J. D. Brown, and R. T. Moon, “Mechanism and function of signal transduction by the Wnt/B-catenin and Wnt/Ca2+ pathways,” Oncogene, vol. 18, no. 55, pp. 7860–7872, 1999.
- Z. You, D. Saims, S. Chen et al., “Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis,” Journal of Cell Biology, vol. 157, no. 3, pp. 429–440, 2002.
- Y. Qiang, Y. Endo, J. S. Rubin, and S. Rudikoff, “Wnt signaling in B-cell neoplasia,” Oncogene, vol. 22, no. 10, pp. 1536–1545, 2003.
- T. C. Dale, “Signal transduction by the Wnt family of ligands,” Biochemical Journal, vol. 329, no. 2, pp. 209–223, 1998.
- X. Q. Gan, J. Y. Wang, Y. Xi, Z. L. Wu, Y. P. Li, and L. Li, “Nuclear Dvl, c-Jun, β-catenin, and TCF form a complex leading to stabilization of β-catenin-TCF interaction,” Journal of Cell Biology, vol. 180, no. 6, pp. 1087–1100, 2008.
- S. Amit, A. Hatzubai, Y. Birman et al., “Axin-mediated CKI phosphorylation of β-catenin at Ser 45: a molecular switch for the Wnt pathway,” Genes and Development, vol. 16, no. 9, pp. 1066–1076, 2002.
- S. Chen, D. C. Guttridge, Z. You et al., “Wnt-1 signaling inhibits apoptosis by activating β-catenin/T cell factor-mediated transcription,” Journal of Cell Biology, vol. 152, no. 1, pp. 87–96, 2001.
- K. Willert, S. Shibamoto, and R. Nusse, “Wnt-induced dephosphorylation of axin releases β-catenin from the axin complex,” Genes and Development, vol. 13, no. 14, pp. 1768–1773, 1999.
- A. Kikuchi, S. Kishida, and H. Yamamoto, “Regulation of Wnt signaling by protein-protein interaction and post-translational modifications,” Experimental and Molecular Medicine, vol. 38, no. 1, pp. 1–10, 2006.
- P. Polakis, “Wnt signaling and cancer,” Genes and Development, vol. 14, no. 15, pp. 1837–1851, 2000.
- D. Lu, Y. Zhao, R. Tawatao et al., “Activation of the Wnt signaling pathway in chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3118–3123, 2004.
- U. Steinhusen, V. Badock, A. Bauer et al., “Apoptosis-induced cleavage of β-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential,” Journal of Biological Chemistry, vol. 275, no. 21, pp. 16345–16353, 2000.
- C. M. Edwards, J. R. Edwards, S. T. Lwin et al., “Increasing wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo,” Blood, vol. 111, no. 5, pp. 2833–2842, 2008.
- M. Schmidt, E. Sievers, T. Endo, D. Lu, D. Carson, and I. G. H. Schmidt-Wolf, “Targeting Wnt pathway in lymphoma and myeloma cells,” The British Journal of Haematology, vol. 144, no. 5, pp. 796–798, 2009.
- T. Oshima, M. Abe, J. Asano et al., “Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2,” Blood, vol. 106, no. 9, pp. 3160–3165, 2005.
- J. Dutta-Simmons, Y. Zhang, G. Gorgun et al., “Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progression,” Blood, vol. 114, no. 13, pp. 2699–2708, 2009.
- Y. W. Qiang, B. Hu, Y. Chen et al., “Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling,” Blood, vol. 113, no. 18, pp. 4319–4330, 2009.
- M. E. Nuttall and J. M. Gimble, “Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications,” Current Opinion in Pharmacology, vol. 4, no. 3, pp. 290–294, 2004.
- G. van der Horst, S. M. van der Werf, H. Farih-Sips, R. L. Van Bezooijen, C. W. G. M. Löwik, and M. Karperien, “Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells,” Journal of Bone and Mineral Research, vol. 20, no. 10, pp. 1867–1877, 2005.
- D. Zechner, Y. Fujita, J. Hülsken et al., “β-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system,” Developmental Biology, vol. 258, no. 2, pp. 406–418, 2003.
- D. A. Glass, P. Bialek, J. D. Ahn et al., “Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation,” Developmental Cell, vol. 8, no. 5, pp. 751–764, 2005.
- J. A. Kennell and O. A. MacDougald, “Wnt signaling inhibits adipogenesis through β-catenin-dependent and -independent mechanisms,” Journal of Biological Chemistry, vol. 280, no. 25, pp. 24004–24010, 2005.
- S. L. Holmen, C. R. Zylstra, A. Mukherjee et al., “Essential role of β-catenin in postnatal bone acquisition,” Journal of Biological Chemistry, vol. 280, no. 22, pp. 21162–21168, 2005.
- A. Jackson, B. Vayssiere, T. Garcia et al., “Gene array analysis of Wnt-regulated genes in C3H10T1/2 cells,” Bone, vol. 36, no. 4, pp. 585–598, 2005.
- N. Sato, T. Yamabuki, A. Takano et al., “Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy,” Cancer Research, vol. 70, no. 13, pp. 5326–5336, 2010.
- S. Aizawa, K. Ookawa, T. Kudo, J. Asano, M. Hayakari, and S. Tsuchida, “Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine,” Cancer Science, vol. 94, no. 10, pp. 886–893, 2003.
- R. A. Nagourney, J. C. Messenger, D. H. Kern, and L. M. Weisenthal, “Enhancement of anthracycline and alkylator cytotoxicity by ethacrynic acid in primary cultures of human tissues,” Cancer Chemotherapy and Pharmacology, vol. 26, no. 5, pp. 318–322, 1990.
- B. D. Hoffman, H. M. Hanauske-Abel, A. Flint, and M. Lalande, “A new class of reversible cell cycle inhibitors,” Cytometry, vol. 12, no. 1, pp. 26–32, 1991.
- Y. Kim, P. Alpmann, S. Blaum-Feder et al., “Increased In vivo efficacy of lenalidomide by addition of piroctone olamine,” In Vivo, vol. 25, no. 1, pp. 99–103, 2011.
- Y. Kim, P. Alpmann, S. Blaum-Feder et al., “In vivo efficacy of griseofulvin against multiple myeloma,” Leukemia Research, vol. 35, no. 8, pp. 1070–1073, 2011.